Therefore, additional studies on the inhibition of LRP8 in immunocompetent models are warranted to fully understand the therapeutic potential of targeting the LRP8/SELENOP axis for therapeutic benefit in neuroblastoma and other malignancies in particular the ones with amplified MYCN. The gene discussed is MYCN; the disease is neuroblastoma.